APP下载

美托洛尔联合曲美他嗪对冠心病心力衰竭患者炎症因子及心功能的影响

2020-04-16汤曾耀刘继文王新旺朱保成刘玉连

中国当代医药 2020年7期
关键词:炎症因子心功能

汤曾耀 刘继文 王新旺 朱保成 刘玉连

[摘要]目的 探討美托洛尔联合曲美他嗪对冠心病心力衰竭患者炎症因子及心功能的影响。方法 选取2016年7月~2018年6月九江市第一人民医院心内科收治的104例冠心病心力衰竭患者作为研究对象,按照随机数字表法分为对照组(52例)和观察组(52例)。对照组采用美托洛尔治疗,观察组采用美托洛尔联合曲美他嗪治疗。比较两组的临床治疗效果、治疗前后的炎症因子水平和心功能指标及不良反应总发生率。结果 观察组的治疗总有效率高于对照组,差异有统计学意义(P<0.05)。两组治疗后的肿瘤坏死因子-α(TNF-α)、白介素-6(IL-6)、超敏C反应蛋白(hs-CRP)水平低于治疗前,观察组治疗后的TNF-α、IL-6和hs-CRP水平低于对照组,差异均有统计学意义(P<0.05)。两组治疗后的左室射血分数(LVEF)高于治疗前,左室收缩末期内径(LVESD)、左室舒张末期内径(LVEDD)低于治疗前,观察组治疗后的LVEF高于对照组,LVESD、LVEDD低于对照组,差异均有统计学意义(P<0.05)。两组的不良反应总发生率比较,差异无统计学意义(P>0.05)。结论 冠心病心力衰竭患者行美托洛尔联合曲美他嗪治疗可有效提高治疗效果,改善心功能,降低炎症因子水平,值得临床推广应用。

[关键词]冠心病心力衰竭;美托洛尔;曲美他嗪;炎症因子;心功能

[中图分类号] R541.4          [文献标识码] A          [文章编号] 1674-4721(2020)3(a)-0048-04

Effect of Metoprolol combined with Trimetazidine on inflammatory factors and cardiac function in patients with coronary heart disease and heart failure

TANG Zeng-yao   LIU Ji-wen   WANG Xin-wang   ZHU Bao-cheng   LIU Yu-lian

Department of Internal Medicine Cardiology, Jiujiang First People′s Hospital of Jiangxi Province, Jiujiang   332000, China

[Abstract] Objective To investigate the effect of Metoprolol combined with Trimetazidine on inflammatory factors and cardiac function in patients with coronary heart disease and heart failure. Methods A total of 104 patients with coronary heart disease and heart failure who were admitted to the Department of Cardiology, Jiujiang First People′s Hospital from July 2016 to June 2018 were selected as the research objects, they were divided into control group (52 cases) and observation group (52 cases) according to the random number table method. The control group was treated with Metoprolol, and the observation group was treated with Metoprolol combined with Trimetazidine. The clinical treatment effect, inflammatory factor levels and cardiac function indexes before and after treatment, and total incidence of adverse reactions were compared between the two groups. Results The total effective rate in the observation group was higher than that in the control group, the difference was statistically significant (P<0.05). The levels of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and high-sensitivity C-reactive protein (hs-CRP) in the two groups after treatment were lower than those before treatment, the levels of TNF-α, IL-6 and hs-CRP in the observation group after treatment were lower than those in the control group, the differences were statistically significant (P<0.05). After treatment, the left ventricular ejection fraction (LVEF) in the two groups was higher than that before treatment, the left ventricular end-systolic diameter (LVESD) and left ventricular end-diastolic diameter (LVEDD) were lower than those before treatment, the LVEF after treatment in the observation group was higher than that in the control group, and LVESD and LVEDD were lower than those in the control group, the differences were statistically significant (P<0.05). There was no significant difference in the overall incidence of adverse reactions between the two groups (P>0.05). Conclusion The treatment of patients with coronary heart disease and heart failure with Metoprolol combined with Trimetazidine can effectively improve the treatment effect, improve cardiac function, and reduce the level of inflammatory factors, which is worthy of clinical application.

[Key words] Coronary heart disease and heart failure; Metoprolol; Trimetazidine; Inflammatory factor; Cardiac function

冠心病的发生主要与动脉粥样硬化有关,导致血管狭窄及阻塞,进而引发心肌缺氧、缺血。心力衰竭属于临床危重症,其发生与心脏器官恶性质变有关,导致患者心功能及左室重构不断减弱,且心脏器官表现出恶性质变,多伴有血流动力学异常、神经内分泌激活、心肌收缩乏力等表现[1]。冠心病患者病情不断发展,将伴发心力衰竭,导致病情进一步加剧,患者的心排血量无法满足其机体正常代谢需求,将造成心肌代谢失常,使心肌细胞处于缺氧状态,心肌收缩机械率受到影响,治疗时应以改善心肌能量代谢的药物为主,保护患者心功能,进而改善患者预后[2]。……

登录APP查看全文

猜你喜欢

炎症因子心功能
老年心力衰竭患者BNP及乳酸水平与心功能的相关性
心功能如何分级?
乌司他丁对急腹症患者围术期炎症因子的影响
胸腔镜微创手术对早期周围型肺癌患者术后炎症反应和免疫功能的影响
胸腹腔镜微创手术与传统开胸手术对食管癌患者术后肺功能、炎症因子水平的影响
阿托伐他汀强化降脂对急性脑梗死患者疗效与炎症因子的影响
血必净治疗重症肺炎的效果观察及对炎症因子和氧化、抗氧化因子的影响
氨氯地平联合阿托伐他汀对高血压合并高血脂患者内皮功能的影响
中西医结合治疗舒张性心功能不全临床观察
磷酸肌酸钠用于老年冠心病合并左心功能不全治疗56例分析